Skip to main content
OpenTrials
Completed

NCT Number: NCT01216670

Cardiac Rhythm Monitoring After Acute Decompensation for Heart Failure

The CARRYING ON for heart failure (HF) study is a national, prospective, post market interventional, multi-center, open-label, pilot trial.The purpose of the study is to assess a short term and a long term period, incidence of pre-specified clinical and arrhythmic events in patients with a low ejection fraction (EF) that are hospitalized for acute cardiac decompensation.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

A.O. SS. Antonio e Biagio e Cesare Arrigo di Alessandria, Alessandria, Italy

Loading trial locations.

About this study

The CARRYING ON for heart failure (HF) study is a national, prospective, post market interventional, multi-center, open-label, pilot trial designed in two phases.

The purpose of the study is to assess a short term (6 months follow-up - Phase 1) and a long term period (24 months follow-up - Phase 2), incidence of pre-specified clinical and arrhythmic events in patients with a low ejection fraction (EF) that are hospitalized for acute cardiac decompensation. A previously implanted Reveal® XT device will be used to collect heart rhythm information.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject with a history of at least one heart failure (HF) hospitalization (as defined in the European Society of Cardiology or American College of Cardiology/American Heart Association guidelines), emergency department (ED) visit, or urgent office visit necessitating intravenous (IV) diuretic or augmentation of oral diuretic, IV inotropic, or IV vasodilator or other HF parenteral therapy within 15 days prior to device implant
  • Subject has an implanted Reveal® XT device (less than 15 days post implant);
  • Ejection Fraction (EF) less than 40 percent
  • Patient with access to a telephone line
  • Patient or the patient's caregiver is willing and able to use the Medtronic CareLink® Network Monitor and to perform the required duties at home or has a family member or assistant perform those duties
  • Age greater than 18 years old
  • Patient is willing and able to comply with the Clinical Investigation plan and willing to remain available for follow-up visit, through study closure
  • Patient (or patient's legally authorized representative) is willing and able to sign and date the study Informed Consent

Exclusion criteria

  • New York Heart Association (NYHA) Class IV (chronic or ambulatory)
  • Planned or previous implant of implantable cardioverter-defibrillator or pacemaker device
  • Patient's life expectancy is less than one year due to non cardiovascular disorders, in the opinion of the physician
  • Severe chronic obstructive pulmonary disorder (COPD)
  • Chronic Atrial Fibrillation at time of enrollment
  • ST segment elevation at time of electrocardiogram
  • Cognitive disease
  • Pregnancy or childbearing potential and not on reliable contraceptive
  • Anticipated compliance problem or participation in another competitive trial

Treatment and study plan

remote patient's management

Behavioral

scheduled remote CareLink data transmission

Other names: home monitoring

Primary outcomes

  1. Phase I: incidence of pre-specified clinical and arrhythmic events

    Time frame: implant to 6 months post-implant

    In patients with low ejection fraction that are hospitalized for acute cardiac decompensation, the pre-specified events include:

    • Cardiovascular mortality or unplanned cardiovascular hospitalizations (including hospitalizations that will be scheduled due to pacemaker, implantable cardioverter-defibrillator, or cardiac resynchronization therapy device implant)
    • Arrhythmic events
  2. Phase II: incidence of pre-specified clinical and arrhythmic events

    Time frame: implant to 24 months post-implant

    In patients with low ejection fraction that are hospitalized for acute cardiac decompensation, the pre-specified events include:

    • Cardiovascular mortality or unplanned cardiovascular hospitalizations (including hospitalizations that will be scheduled due to pacemaker, implantable cardioverter-defibrillator, or cardiac resynchronization therapy device implant)
    • Arrhythmic events

Secondary outcomes

  1. Phase I: incidence of the pre-specified secondary clinical and arrhythmic events in patients implanted with the Reveal® XT

    Time frame: implant to 6 months post-implant

    Document the incidence of the pre-specified secondary clinical and arrhythmic events in patients implanted with the Reveal XT.

    The pre-specified secondary clinical and arrhythmic events are:

    • Time to first detection of brady-tachyarrhythmia episode;
    • All cause mortality or unplanned cardiovascular hospitalization;
    • Unplanned cardiovascular hospitalization;
    • Heart Failure hospitalization;
    • Cardiovascular mortality;
    • Serious cardiovascular Adverse Events.
  2. Phase II: incidence of the pre-specified secondary clinical and arrhythmic events in patients implanted with the Reveal® XT

    Time frame: implant to 24 months post-implant

    Document the incidence of the pre-specified secondary clinical and arrhythmic events in patients implanted with the Reveal XT.

    The pre-specified secondary clinical and arrhythmic events are:

    • Time to first detection of brady-tachyarrhythmia episode;
    • All cause mortality or unplanned cardiovascular hospitalization;
    • Unplanned cardiovascular hospitalization;
    • Heart Failure hospitalization;
    • Cardiovascular mortality;
    • Serious cardiovascular Adverse Events

Sponsors and collaborators

Lead sponsor

Medtronic Italia

Industry

Registry information

Acronym: CARRYINGON

Important dates

Study start
2011
Primary completion
2013
Study completion
2014
First posted
Oct 7, 2010
Registry last updated
Oct 14, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.